The Trouble With Tropism

[Guest guest]

Excellent article that everyone thinking about taking Maraviroc (Selzentry), the

new entry inhibitor, should read....

September 26, 2007

The Trouble With Tropism

by

For HIV-positive people in need of new treatment options, last month’s arrival

of Selzentry

(maraviroc) in the United States was a sight for sore eyes. The new

drug, manufactured by Pfizer, is the first in a whole new class of

antiretrovirals—called “CCR5 antagonists”—to gain approval from the Food and

Drug Adminstration

(FDA). In 1996, scientists discovered how HIV binds with and

subsequently infects CD4 cells with the use of a co-receptor dubbed

CCR5 (R5 for short). Selzentry, a product of this research and also approved

this week as Celsentri in the European Union, halts HIV from attaching itself to

CD4 cells at the R5 site, thus blocking cellular entry of the virus and

preventing HIV replication

More: http://www.poz.com/articles/tropism_CCR5_maraviroc_401_13114.shtml

Regards,

Vergel

powerusa dot org